Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex™

Sigue a La Raza en Facebook

CHARLESTON, S.C.–(BUSINESS WIRE)–#AEZSAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”)
will announce the top-line results of the ZoptEC Phase 3 clinical study
of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced,
recurrent or metastatic endometrial cancer prior to the commencement of
trading on Monday, May 1, 2017.

Conference Call

The Company will host a conference call to discuss the results of the
ZoptEC Phase 3 clinical study of Zoptrex™ on Monday, May 1, 2017, at
8:30 AM, Eastern Time. Participants may access the conference call by
using the following number: 201-689-8029, Confirmation 13660857.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel treatments in oncology,
endocrinology and women’s health. We are engaged in drug development
activities and in the promotion of products for others. We recently
completed Phase 3 studies of two internally developed compounds. The
focus of our business development efforts is the acquisition of licenses
to products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in non-US territories where such out-licensing
would enable us to ensure development, registration and launch of our
product candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.

Contacts

Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior
Vice President
ir@aezsinc.com